Calithera Biosciences (CALA) Reports Complete Patient Enrollment in Randomized Phase 2 ENTRATA Trial of Telaglenastat (CB-839) and Everolimus in Renal Cell Carcinoma

February 4, 2019 7:20 AM

Calithera Biosciences, Inc. (NASDAQ: CALA) today announced that it has completed patient enrollment in the ongoing Phase 2 ENTRATA trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found